Acute endovascular reperfusion therapy in ischemic stroke: a systematic review and meta-analysis of randomized controlled trials

• Published in: PloS one 2015-04, Vol.10 (4), p.e0122806-e0122806
• Main Authors: Osanai, Toshiya, Pasupuleti, Vinay, Deshpande, Abhishek, Thota, Priyaleela, Roman, Yuani, Hernandez, Adrian V, Uchino, Ken
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia - drug therapy; Brain Ischemia - surgery; Cardiovascular system; Clinical trials; Endovascular Procedures - adverse effects; Endovascular Procedures - methods; Fibrinolytic Agents - adverse effects; Fibrinolytic Agents - therapeutic use; Hemorrhage; Humans; Intracranial Hemorrhages - drug therapy; Intracranial Hemorrhages - surgery; Ischemia; Meta-analysis; Middle Aged; Mortality; Quality; Randomization; Randomized Controlled Trials as Topic; Reperfusion; Reperfusion - methods; Stroke; Stroke - drug therapy; Stroke - surgery; Therapy; Thrombolysis; Thrombolytic Therapy - adverse effects; Thrombolytic Therapy - methods; Young Adult
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0122806

Randomized controlled trials (RCTs) of endovascular therapy for acute ischemic stroke have had inconsistent results. We evaluated the efficacy and safety of endovascular therapy in published RCTs. We performed a systematic review of RCTs of endovascular therapy with thrombolytic or mechanical reperfusion compared with interventions without endovascular therapy. Primary outcome was the frequency of good functional outcome (modified Rankin scale (mRS) of 0-2 at 90 days) and secondary outcomes were mortality at 90 days and symptomatic intracranial hemorrhage (sICH). Random-effects meta-analysis was performed and the Cochrane risk of bias assessment was used to evaluate quality of evidence. Ten studies involving 1,612 subjects were included. Endovascular therapy was not significantly associated with good functional outcome (Relative Risk [RR] =1.17; 95% CI, 0.97 to 1.42; p=0.10 and Absolute Risk Difference [ARD] =7%; 95%CI -0.1% to 14%; p=0.05); heterogeneity was moderate among studies (I2=30%). Mortality was unchanged with endovascular therapy (RR=0.92; 95 % CI, 0.75 to 1.13; p=0.45) and there was no difference in sICH (RR=1.20; 95 % CI, 0.79 to 1.82; p=0.39). The quality of evidence was low for all outcomes and the recommendation is weak for the use of endovascular therapy as per GRADE methodology. Intra-arterial therapy did not show significant increase in good outcomes and no changes in either mortality or sICH in patients with acute ischemic stroke. We need further RCTs with better design and quality to evaluate the true efficacy of endovascular therapy.